导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.04% | 2869/4766 |
| 近一周 | -1.88% | 3661/5457 |
| 近一月 | -5.68% | 2548/5411 |
| 近一季 | -8.51% | 2709/5229 |
| 近半年 | -2.35% | 2286/4923 |
| 近一年 | 0.11% | 2568/4393 |
| 近两年 | 47.58% | 1557/2948 |
| 近三年 | 28.54% | 1122/2248 |
| 成立以来 | 126.78% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.75% 3388/4961 |
12.58% 2153/5312 |
- - |
- - |
| 2025 | 20.77% 2093/4813 |
-1.01% 2529/3635 |
2.32% 1649/4076 |
19.02% 2202/4524 |
0.18% 2156/4813 |
| 2024 | 17.30% 706/3463 |
2.93% 663/2808 |
-1.27% 1016/3014 |
17.69% 1144/3129 |
-1.92% 1887/3463 |
| 2023 | -9.52% 1181/2656 |
4.53% 930/2280 |
-4.11% 1053/2385 |
-3.05% 837/2515 |
-6.89% 1962/2655 |
| 2022 | -20.29% 958/2207 |
-14.60% 977/1919 |
7.07% 536/2016 |
-14.37% 1082/2113 |
1.80% 1136/2208 |
| 2021 | -3.62% 919/1822 |
-3.25% 788/1255 |
4.37% 894/1330 |
-6.03% 892/1466 |
1.57% 872/1822 |
| 2020 | 29.16% 544/1250 |
-10.12% 759/1028 |
13.89% 585/1067 |
11.22% 465/1164 |
13.45% 359/1184 |
| 2019 | 38.10% 318/1092 |
28.23% 321/754 |
-0.23% 241/804 |
0.65% 492/850 |
7.25% 462/918 |
| 2018 | -24.03% 314/834 |
- - |
- - |
- - |
-12.46% 445/691 |
| 2017 | 23.36% 137/714 |
- - |
- - |
- - |
- - |
| 2016 | -9.39% 260/605 |
- - |
- - |
- - |
- - |
| 2015 | 6.99% 184/575 |
- - |
- - |
- - |
- - |
| 2014 | 54.58% 55/237 |
- - |
- - |
- - |
- - |
| 2013 | -5.60% 100/186 |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 嘉实沪深300ETF VS. 长安沪深300非周期A(740101) |